Jan. 30 at 4:12 PM
$TELO I studied this and I see two major problems:
1) The science is not compelling. I am not saying it is bad science, I am saying that what they see preclinically is modest so I would not expect it to somehow work better in the natural disease setting.
2) They have about 6 months cash and are funding about
$3M per quarter ATM according to their 10Q, which is not too much, but it is putting that downward pressure on the stock.
It is possible the IND news could cause a big short run on the stock, you never know how these things go, but until then this will probably just trickle down. It could be six months from now. I will keep watch on it but not take a position
